---
figid: PMC4409143__nihms552457f3
figtitle: Therapies targeting the PI3K/AKT/mTOR pathway
organisms:
- NA
pmcid: PMC4409143
filename: nihms552457f3.jpg
figlink: /pmc/articles/PMC4409143/figure/F3/
number: F3
caption: Therapies targeting the PI3K/AKT/mTOR pathway. Most patients (104, 76%) received
  mTORC1 inhibitor (rapalog)-based therapy, 20 (15%) PI3K inhibitor-based therapy,
  6 (4.5%) dual PI3K and mTOR kinase inhibitor-based therapy, and 6 (4.5%) AKT inhibitor-based
  therapy.
papertitle: 'PIK3CA, and PTEN Aberrations in Early-Phase Trials with PI3K/AKT/mTOR
  Inhibitors: Experience with 1,656 Patients at MD Anderson Cancer Center.'
reftext: Filip Janku, et al. Cell Rep. ;6(2):377-387.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9353291
figid_alias: PMC4409143__F3
figtype: Figure
organisms_ner:
- Drosophila melanogaster
redirect_from: /figures/PMC4409143__F3
ndex: ca21771d-df06-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4409143__nihms552457f3.html
  '@type': Dataset
  description: Therapies targeting the PI3K/AKT/mTOR pathway. Most patients (104,
    76%) received mTORC1 inhibitor (rapalog)-based therapy, 20 (15%) PI3K inhibitor-based
    therapy, 6 (4.5%) dual PI3K and mTOR kinase inhibitor-based therapy, and 6 (4.5%)
    AKT inhibitor-based therapy.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - pk
  - pi
  - Pten
  - Akt
  - Crtc
---
